30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

Active Implants Receives FDA Breakthrough Device Designation for NUsurface Meniscus Implant -

Active Implants was granted a Breakthrough Device Designation from FDA for the NUsurface® Meniscus Implant. If cleared by FDA, NUsurface would be the first artificial meniscus in the U.S. market. FDA's Breakthrough Devices Program was created to expedite the development and review process for medical devices that are novel or offer new technology for patients with life-threatening or irreversibly debilitating conditions. It is designed to ensure that patients and healthcare providers have timely access to vital devices. NUsurface is an investigational treatment in the U.S. for patients with persistent knee pain following medial meniscus surgery. Made from polymer and as a result of its materials, composite structure and design, it does not require fixation to bone or soft tissue. The implant mimics the function of the natural meniscus and redistributes loads across the knee joint. (Active Implants LLC, 9/19/19)